Log in

Relevant bibliographies by topics / Anticancer drugs / Journal articles

To see the other types of publications on this topic, follow the link: Anticancer drugs.

Journal articles on the topic 'Anticancer drugs'

Author: Grafiati

Published: 4 June 2021

Last updated: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Anticancer drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

D, Subba Reddy, Prasanthi G, Amruth Raj S, Hari Krishna T, Sowjanya K, and Shantha Kumari K. "EVALUATION OF ANTICANCER GENERIC DRUGS AND BRANDED DRUGS." Indian Research Journal of Pharmacy and Science 5, no. 1 (March 2018): 1378–91. http://dx.doi.org/10.21276/irjps.2018.5.1.16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Reese, David M. "Anticancer drugs." Nature 378, no. 6557 (December 1995): 532. http://dx.doi.org/10.1038/378532c0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kutty, Dr A. V. M. "Usefulness of Phytochemicals as Anticancer Drugs." JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 16, no. 1 (March 19, 2019): 1–2. http://dx.doi.org/10.58739/jcbs/v09i1.7.

Full text

Abstract:

Cancer is a state of uncontrolled proliferation and dedifferentiation of cells in any tissues or organs of the body. The incidence of cancer is rising alarmingly and is one of the leading causes of morbidity and mortality globally. Normal cell division is precisely a planned biological process controlled by regulatory genes and specific metabolic pathways. Exposure of normally functioning cells to carcinogens leads to mutations in the genes causing loss of control of cell division and transform into cancerous. Over a period of time, these cancer cells acquire more mutations; invade to adjoining tissues, escape the process of apoptosis and the cells become eternal. Breakaway parts of the cancer tissues / cells travel through the lymphatic and blood vessels and get deposited in other tissues / organs leading to metastasis, the spread of cancer.

APA, Harvard, Vancouver, ISO, and other styles

4

Atkins, Joshua H., and Leland J. Gershell. "Selective anticancer drugs." Nature Reviews Drug Discovery 1, no. 7 (July 2002): 491–92. http://dx.doi.org/10.1038/nrd842.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Atkins, Joshua H., and Leland J. Gershell. "Selective anticancer drugs." Nature Reviews Cancer 2, no. 9 (September 2002): 645–46. http://dx.doi.org/10.1038/nrc900.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bibby, M. C. "Combretastatin anticancer drugs." Drugs of the Future 27, no. 5 (2002): 475. http://dx.doi.org/10.1358/dof.2002.027.05.668645.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Meegan, Mary J., and Niamh M. O’Boyle. "Special Issue “Anticancer Drugs”." Pharmaceuticals 12, no. 3 (September 16, 2019): 134. http://dx.doi.org/10.3390/ph12030134.

Full text

Abstract:

The focus of this Special Issue of Pharmaceuticals is on the design, synthesis, and molecular mechanism of action of novel antitumor, drugs with a special emphasis on the relationship between the chemical structure and the biological activity of the molecules. This Special Issue also provides an understanding of the biologic and genotypic context in which targets are selected for oncology drug discovery, thus providing a rationalization for the biological activity of these drugs and guiding the design of more effective agents. In this Special Issue of Pharmaceuticals dedicated to anticancer drugs, we present a selection of preclinical research papers including both traditional chemotherapeutic agents and newer more targeted therapies and biological agents. We have included articles that report the design of small molecules with promising anticancer activity as tubulin inhibitors, vascular targeting agents, and topoisomerase targeting agents, alongside a comprehensive review of clinically successful antibody-drug conjugates used in cancer treatment.

APA, Harvard, Vancouver, ISO, and other styles

8

Ciarimboli, Giuliano. "Anticancer Platinum Drugs Update." Biomolecules 11, no. 11 (November 4, 2021): 1637. http://dx.doi.org/10.3390/biom11111637.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Zhang, Jason Y. "Apoptosis-based anticancer drugs." Nature Reviews Drug Discovery 1, no. 2 (February 2002): 101–2. http://dx.doi.org/10.1038/nrd742.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Blagosklonny, Mikhail V. "Teratogens as Anticancer Drugs." Cell Cycle 4, no. 11 (August 22, 2005): 1518–21. http://dx.doi.org/10.4161/cc.4.11.2208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

KOPEČEK, JINDŘICH. "Targetable Polymeric Anticancer Drugs." Annals of the New York Academy of Sciences 618, no. 1 Temporal Cont (February 1991): 335–44. http://dx.doi.org/10.1111/j.1749-6632.1991.tb27253.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Mundy, Gregory R., and Toshiyuki Yoneda. "Bisphosphonates as Anticancer Drugs." New England Journal of Medicine 339, no. 6 (August 6, 1998): 398–400. http://dx.doi.org/10.1056/nejm199808063390609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Miyamoto, Shingo, Manabu Yamada, Yasuyo Kasai, Akito Miyauchi, and Kazumichi Andoh. "Anticancer drugs during pregnancy." Japanese Journal of Clinical Oncology 46, no. 9 (June 9, 2016): 795–804. http://dx.doi.org/10.1093/jjco/hyw073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Xing, Z., D. Li, L. Yang, Y. Xi, and X. Su. "MicroRNAs and anticancer drugs." Acta Biochimica et Biophysica Sinica 46, no. 3 (February 3, 2014): 233–39. http://dx.doi.org/10.1093/abbs/gmu003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Wallis, Denise, James Claffey, Brendan Gleeson, Megan Hogan, Helge Müller-Bunz, and Matthias Tacke. "Novel zirconocene anticancer drugs?" Journal of Organometallic Chemistry 694, no. 6 (March 2009): 828–33. http://dx.doi.org/10.1016/j.jorganchem.2008.08.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Bradley, David. "Self-assembling anticancer drugs." Materials Today 41 (December 2020): 3. http://dx.doi.org/10.1016/j.mattod.2020.10.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Russell, Stephen J., and Kah-Whye Peng. "Viruses as anticancer drugs." Trends in Pharmacological Sciences 28, no. 7 (July 2007): 326–33. http://dx.doi.org/10.1016/j.tips.2007.05.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Kerwin, Sean. "Toward Bioengineering Anticancer Drugs." Chemistry & Biology 9, no. 9 (September 2002): 956–58. http://dx.doi.org/10.1016/s1074-5521(02)00222-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Rohr, Jürgen. "Cryptophycin Anticancer Drugs Revisited." ACS Chemical Biology 1, no. 12 (December 2006): 747–50. http://dx.doi.org/10.1021/cb6004678.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Denny, William A. "Hypoxia-activated anticancer drugs." Expert Opinion on Therapeutic Patents 15, no. 6 (June 2005): 635–46. http://dx.doi.org/10.1517/13543776.15.6.635.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Bordon, Yvonne. "Anticancer drugs copy bugs." Nature Reviews Cancer 14, no. 12 (November 24, 2014): 767. http://dx.doi.org/10.1038/nrc3866.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Van der Veldt, Astrid A. M., Adriaan A. Lammertsma, and Egbert F. Smit. "Scheduling of anticancer drugs." Cell Cycle 11, no. 23 (December 2012): 4339–43. http://dx.doi.org/10.4161/cc.22187.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Mundy, Gregory R. "Bisphosphonates as anticancer drugs." Expert Opinion on Investigational Drugs 8, no. 12 (December 1999): 2009–15. http://dx.doi.org/10.1517/13543784.8.12.2009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Bordon, Yvonne. "Anticancer drugs need bugs." Nature Reviews Immunology 14, no. 1 (December 13, 2013): 1. http://dx.doi.org/10.1038/nri3591.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Bordon, Yvonne. "Anticancer drugs copy bugs." Nature Reviews Immunology 14, no. 12 (November 14, 2014): 776–77. http://dx.doi.org/10.1038/nri3775.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Jefford, Michael, Linda Mileshkin, Penelope Schofield, Emilia Agalianos, Jacqui Thomson, and John Zalcberg. "Discussing Expensive Anticancer Drugs." Journal of Clinical Oncology 27, no. 3 (January 20, 2009): 476–77. http://dx.doi.org/10.1200/jco.2008.20.1780.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Schwartsmann, G. "Anticancer drugs from nature." Medical and Pediatric Oncology 37, no. 1 (2001): 79–80. http://dx.doi.org/10.1002/mpo.1173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Janus, Nicolas. "Gastrointestinal Disorders and Toxicities Induced By Anticancer Drugs. Another Risk Factor of Bleeding in Cancer-Associated Thrombosis." Blood 136, Supplement 1 (November 5, 2020): 36. http://dx.doi.org/10.1182/blood-2020-141814.

Full text

Abstract:

Introduction Anticancer treatments has been changing since decades, evolving from chemotherapy (platinum salts) to recent check-point inhibitors. Nausea, vomiting and diarrhoea are common adverse events of anticancer drugs, despites the fact that some supportive care drugs can manage these adverse events. Gastro-intestinal (GI) disorders/toxicities are also important. Such as gastric/duodenal ulcer, gastritis, stomatitis, colitis, esophagitis... Cancer-associated-thrombosis (CAT) patients were also reported to be exposed to such GI disorders/toxicities and several publications recommended to consider these GI disorders/toxicities when choosing an anticoagulant in CAT (Carrier M. Curr Oncol 2018; Moik F. ESMO Open 2020). However, little is known about the nature of the anticancer drugs that CAT patients are receiving. The aim of this work was to check all the anticancer's SmPCs (Summary of Product Characteristics) on the EMA website for GI disorders. Methods All SmPCs of anticancer drugs indicated for lung cancer were checked on the EMA website. All adverse events regarding GI disorders/toxicities were collected. The frequency of adverse events used was the following: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1000); very rare (< 1/10,000). However, it was decided to mainly focus on very common and common ones. Old anticancer drugs SmPCs (platinium salts...) were checked on electronic medicines compendium (medicines.org.uk), because these old SmPCs are not always available on the EMA website. Generics, biosimilars and drugs without a licence were excluded. Results Twenty-eight anticancer drugs were identified with a mix of traditional chemotherapies (platinum salts...), tyrosine kinase inhibitors (nib) and monoclonal antibodies (mab). Among these 28 anticancer drugs, 26 had at least one very common/common GI disorders/toxicities. Obviously, vomiting (82.1%) and diarrhoea (89.3%) are very well-known, but it was interesting to see that many anticancer drugs were associated with other very common/common GI toxicities such as stomatitis (71.4%) and colitis (10.7%). Additionally, several drugs (35.7%) were exposing to GI bleeding and/or GI perforation but these last adverse events were less common. Unfortunately, the SmPCs did not include data about the GI profile of the patients during the trials. Conclusion Monreal M et al reported in 1991 that acute gastroduodenal lesion was found in 21% of patients with venous thromboembolism, but there are no dedicated study about the incidence of GI disorders in CAT patients. This work reported that GI disorders/toxicities were common in anticancer drug's SmPCs. Consequently, it is important to be aware of this before initiating an anticoagulant treatment. However, this work had limitations. Indeed, these adverse events were reported in the SmPCs, based mainly on cancer trials and not on CAT trials. Furthermore, clinical trials and SmPCs may not always reflect the real clinical setting. Finally, lung cancer patients are usually receiving anticancer regimens that include several anticancer drugs, so the potential impact of GI disorders/toxicities from 2 or 3 anticancer drugs on a single patients could be greater. Nevertheless, it sounds reasonable to check for GI disorders/toxicities risks in order to initiate an adequate anticoagulant treatment in CAT patients and during follow-up. Disclosures Janus: Guerbet:Research Funding;B-Braun:Honoraria;LEO Pharma A/S:Current Employment, Honoraria;Fresenius Medical Care:Honoraria;Amgen:Honoraria, Research Funding;TEVA:Research Funding;Daichii-Sankyo:Honoraria, Research Funding;Roche:Honoraria, Research Funding;Vifor Pharma:Honoraria, Research Funding;Gilead:Honoraria, Research Funding;Novartis:Honoraria;Pierre Fabre Oncology:Research Funding;Bayer:Honoraria, Research Funding;Pfizer:Consultancy, Honoraria;IPSEN:Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

29

Li, Dong Hong, Jun Lin Diao, Ke Gui Yu, and Cheng He Zhou. "Synthesis and anticancer activities of porphyrin induced anticancer drugs." Chinese Chemical Letters 18, no. 11 (November 2007): 1331–34. http://dx.doi.org/10.1016/j.cclet.2007.09.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Anticancer drugs from the sea." Inpharma Weekly &NA;, no. 1417 (December 2003): 4. http://dx.doi.org/10.2165/00128413-200314170-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Evans, William E., and Mary V. Relling. "Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer Drugs." Clinical Pharmacokinetics 16, no. 6 (June 1989): 327–36. http://dx.doi.org/10.2165/00003088-198916060-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Carcone, Bernard, and Dionyssis Pongas. "Cardiovascular toxicity of anticancer drugs." Sang thrombose vaisseaux 26, no. 4 (July 2014): 188–96. http://dx.doi.org/10.1684/stv.2014.0849.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Amelio, Ivano, Andrey Lisitsa, Richard Knight, Gerry Melino, and Alexey Antonov. "Polypharmacology of Approved Anticancer Drugs." Current Drug Targets 18, no. 5 (February 24, 2017): 534–43. http://dx.doi.org/10.2174/1389450117666160301095233.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Jeanny B. Aragon-Ching, Haiqing Li, Erin R. Gardner, and William D. Figg. "Thalidomide Analogues as Anticancer Drugs." Recent Patents on Anti-Cancer Drug Discovery 2, no. 2 (June 1, 2007): 167–74. http://dx.doi.org/10.2174/157489207780832478.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Meegan, Mary J., and Niamh M. O’Boyle. "Special Issue “Anticancer Drugs 2021”." Pharmaceuticals 15, no. 4 (April 14, 2022): 479. http://dx.doi.org/10.3390/ph15040479.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Benjamin Garbutcheon-Singh, K., Maxine P. Grant, Benjamin W. Harper, Anwen M. Krause-Heuer, Madhura Manohar, Nikita Orkey, and Janice R. Aldrich-Wright. "Transition Metal Based Anticancer Drugs." Current Topics in Medicinal Chemistry 11, no. 5 (March 1, 2011): 521–42. http://dx.doi.org/10.2174/156802611794785226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Fujita, Ken-ichi. "Cytochrome P450 and Anticancer Drugs." Current Drug Metabolism 7, no. 1 (January 1, 2006): 23–37. http://dx.doi.org/10.2174/138920006774832587.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Wallace, H. M., and A. V. Fraser. "Polyamine analogues as anticancer drugs." Biochemical Society Transactions 31, no. 2 (April 1, 2003): 393–96. http://dx.doi.org/10.1042/bst0310393.

Full text

Abstract:

Just over 30 years ago, the late Diane Russell published the first in a series of papers linking polyamines and cancer. These early studies led to a flurry of research activity in the polyamine field that continues to this day attempting to identify a role for the polyamines in cancer development, treatment and/or prevention. The recognition that polyamines are critical for the growth of cancer cells, and consequently the identification of their metabolic pathways as a target for therapeutic intervention, led to the development of a number of useful inhibitors of polyamine biosynthesis. Arguably the most significant addition to the polyamine field in the last 30 years was the synthesis of α-difluoromethylornithine (DFMO), which is being tested currently as a cancer chemopreventative agent in man and is used also as a highly effective trypanocidal agent. Although an extremely useful tool experimentally, DFMO has been disappointing in clinical trials with little therapeutic efficacy. Despite this setback, the polyamine pathway is still considered a viable target for chemotherapeutic intervention. This has led to the development of the polyamine analogues as multifunctional inhibitors that will produce inhibition of tumour cell growth, polyamine depletion and optimum therapeutic efficacy.

APA, Harvard, Vancouver, ISO, and other styles

39

Hyodo, Kenji, Eiichi Yamamoto, Takuya Suzuki, Hiroshi Kikuchi, Makoto Asano, and Hiroshi Ishihara. "Development of Liposomal Anticancer Drugs." Biological and Pharmaceutical Bulletin 36, no. 5 (2013): 703–7. http://dx.doi.org/10.1248/bpb.b12-01106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Powis, Garth, Miles P. Hacker, and Graziano C. Carlon. "The Toxicity of Anticancer Drugs." Critical Care Medicine 21, no. 7 (July 1993): 1101. http://dx.doi.org/10.1097/00003246-199307000-00034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Baumann, F., and R. Preiss. "Cyclophosphamide and related anticancer drugs." Journal of Chromatography B: Biomedical Sciences and Applications 764, no. 1-2 (November 2001): 173–92. http://dx.doi.org/10.1016/s0378-4347(01)00279-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Tjaden, U. R., and E. A. De Bruijn. "Chromatographic analysis of anticancer drugs." Journal of Chromatography B: Biomedical Sciences and Applications 531 (October 1990): 235–94. http://dx.doi.org/10.1016/s0378-4347(00)82286-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Sapra, P., and T. M. Allen. "Ligand-targeted liposomal anticancer drugs." Progress in Lipid Research 42, no. 5 (September 2003): 439–62. http://dx.doi.org/10.1016/s0163-7827(03)00032-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Tanigawara, Y. "Pharmaco-Metabolomics for Anticancer Drugs." Annals of Oncology 23 (October 2012): xi55. http://dx.doi.org/10.1016/s0923-7534(20)32076-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Yoshioka, T. "Drugs Interaction of Anticancer Agents." Annals of Oncology 23 (October 2012): xi65. http://dx.doi.org/10.1016/s0923-7534(20)32111-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Muers, Mary. "Transgenerational effects of anticancer drugs." Nature Reviews Genetics 13, no. 3 (February 14, 2012): 148. http://dx.doi.org/10.1038/nrg3190.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Gosland, Michael P., and Bert L. Lum. "The Anticancer Drugs, 2nd Edition." Annals of Pharmacotherapy 29, no. 3 (March 1995): 320. http://dx.doi.org/10.1177/106002809502900321.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Meyer, G. "Pulmonary Toxicity of Anticancer Drugs." Annals of Oncology 25 (September 2014): iv33. http://dx.doi.org/10.1093/annonc/mdu310.2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Imran, Muhammad, Wagma Ayub, Ian S. Butler, and Zia-ur-Rehman. "Photoactivated platinum-based anticancer drugs." Coordination Chemistry Reviews 376 (December 2018): 405–29. http://dx.doi.org/10.1016/j.ccr.2018.08.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

SALVIK, MILAN, JUN WU, and CHRISTOPHER RILEY. "Salivary Excretion of Anticancer Drugs." Annals of the New York Academy of Sciences 694, no. 1 Saliva as a D (September 1993): 319–21. http://dx.doi.org/10.1111/j.1749-6632.1993.tb18377.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!